Myelination deficit in a phencyclidine-induced neurodevelopmental model of schizophrenia

Ruiguo Zhang1, Jue He, Shenghua Zhu

  • 1Department of Psychiatry, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, PR China.

Brain Research
|July 4, 2012
PubMed

Insights

Schizophrenia may involve problems with myelin, the protective sheath around nerve cells. This study found impaired myelination in a rat model, suggesting a link between myelin dysfunction and schizophrenia development.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cell Biology

Background:

  • Oligodendrocytes produce myelin in the central nervous system.
  • Myelination is increasingly implicated in schizophrenia pathogenesis.
  • The myelination dysfunction hypothesis requires further investigation.

Purpose of the Study:

  • To investigate myelination dysfunction in a phencyclidine (PCP)-induced neurodevelopmental model of schizophrenia.
  • To assess the role of oligodendrocytes and myelination in schizophrenia-like behaviors.

Main Methods:

  • Rats received daily PCP injections from postnatal day 2.
  • Schizophrenia-like behaviors (hyperactivity, prepulse inhibition deficit) were assessed.
  • Myelination was measured via myelin basic protein (MBP) expression.
  • Mature oligodendrocytes were quantified using glutathione S-transferase (GST)-π expression.

Main Results:

  • PCP-treated rats exhibited schizophrenia-like behaviors.
  • Reduced MBP expression was observed on postnatal days 16, 22, and 32.
  • Decreased GST-π expression was noted on postnatal day 22 in the frontal cortex.
  • These findings indicate impaired cerebral myelination.

Conclusions:

  • The phencyclidine-induced rat model demonstrates myelination impairment.
  • Myelination dysfunction is suggested to play a significant role in schizophrenia pathogenesis.
  • Oligodendrocyte dysfunction may be a key factor in schizophrenia development.